Stem cell concepts renew cancer research

Blood

Volumn 112, Issue 13, 2008, Pages 4793-4807

  Dick, John E ^a,b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Toronto Medical Discovery   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ERLOTINIB; IMATINIB; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER RESEARCH; CANCER STEM CELL; CELL DIFFERENTIATION; CELL FRACTIONATION; CELL HETEROGENEITY; CELL KILLING; CELL KINETICS; CELL PROLIFERATION; CELL STRUCTURE; CLONOGENIC ASSAY; COLONY FORMING UNIT; DESMOSOME; DRUG TARGETING; EPIGENETICS; HUMAN; MEDICAL RESEARCH; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; STEM CELL; TUMOR CELL; TUMOR GROWTH; BIOLOGICAL MODEL; CYTOLOGY; HEMATOPOIETIC STEM CELL; NEOPLASM; PATHOLOGY; REVIEW;

HEMATOPOIETIC STEM CELLS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 58149380742     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-08-077941     Document Type: Article

References (171)

1. Wang JC, Dick JE. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 2005;15:494-501.
2. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med. 2007;58:267-284.
3. Ailles LE, Weissman IL. Cancer stem cells in solid tumors. Curr Opin Biotechnol. 2007;18:460-466.
4. Furth J, Kahn M. The transmission of leukemia of mice with a single cell. Am J Cancer. 1937;31: 276-282.
5. Makino S. Further evidence favoring the concept of the stem cell in ascites tumors of rats. Ann N Y Acad Sci. 1956;63:818-830.
6. Hewitt HB. Studies of the dissemination and quantitative transplantation of a lymphocytic leukaemia of CBAm ice. Br J Cancer. 1958;12:378-401.
7. Bruce WR, Van Der Gaag H.Aquantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature. 1963;199:79-80.
8. Southam C, Brunschwig A, Dizon Q.Autologous and homologous transplantation of human cancer. In: Brennan MJ, Simpson WL, eds. Biological Interactions in Normal and Neoplastic Growth: A Contribution to the Tumor-Host Problem. Boston, MA: Little, Brown;1962:723-738.
9. Pierce GB Jr, Dixon FJ Jr, Verney EL. Teratocar-cinogenic and tissue-forming potentials of the cell types comprising neoplastic embryoid bodies. Lab Invest. 1960;9:583-602.
10. Pierce GB, Speers WC. Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Res. 1988;48:1996-2004.
11. Belanger L, Leblond C. A method for locating radioactive elements in tissues by covering histo-logical sections with a photographic emulsion. Endocrinology. 1946;39:386-400.
12. Clermont Y, Leblond C. Renewal of spermatagonia in the rat testis. Am J Anat. 1953;93:475-502.
13. Clarkson B, Fried J, Strife A, Sakai Y, Ota K, Okita T. Studies of cellular proliferation in human leukemia: III. Behavior of leukemic cells in three adults with acute leukemia given continuous infusions of 3H-thymidine for 8 or 10 days. Cancer. 1970;25: 1237-1260.
14. Clarkson BD, Fried J. Changing concepts of treatment in acute leukemia. Med Clin North Am. 1971;55:561-600.
15. Killmann SA, Cronkite EP, Robertson JS, Fliedner TM, Bond VP. Estimation of phases of the life cycle of leukemic cells from labeling in human beings in vivo with tritiated thymidine. Lab Invest. 1963;12:671-684.
16. Gavosto F. The proliferative kinetics of the acute leukaemias in relation to their treatment. Rev Eur Etud Clin Biol. 1970;15:1042-1047.
17. Clarkson BD. Review of recent studies of cellular proliferation in acute leukemia. Natl Cancer Inst Monogr. 1969;30:81-120.
18. Clarkson B. The survival value of the dormant state in neoplastic and normal populations. In: Clarkson B, Baserga R, eds. Control of Proliferation in Animal Cells. New York, NY: Cold Spring Harbor Laboratory;1974;945-972.
19. Cronkite EP. Acute leukemia: is there a relationship between cell growth kinetics and response to chemotherapy? Proc Natl Cancer Conf. 1970;6: 113-117.
20. Clarkson BD, Dowling MD, Gee TS, Cunningham IB, Burchenal JH. Treatment of acute leukemia in adults. Cancer. 1975;36:775-795.
21. Buick RN, Till JE, McCulloch EA. Colony assay for proliferative blast cells circulating in myeloblastic leukaemia. Lancet. 1977;1:862-863.
22. McCulloch E. Stem cells in normal and leukemic hemopoiesis (Henry Stratton Lecture). Blood. 1983;62:1-13.
23. Metcalf D, Moore MA, Warner NL. Colony formation in vitro myelomonocytic leukemic cells. J Natl Cancer Inst. 1969;43:983-1001.
24. Moore MA, Williams N, Metcalf D. In vitro colony formation by normal and leukemic human hematopoietic cells: characterization of the colonyforming cells. J Natl Cancer Inst. 1973;50:603-623.
25. Griffin J, Löenberg B. Clonogenic cells in acute myeloblastic leukemia. Blood. 1986;68:1185-1195.
26. Dicke KA, Spitzer G, Ahearn MJ. Colony formation in vitro by leukaemic cells in acute myelogenous leukaemia with phytohaemagglutinin as stimulating factor. Nature. 1976;259:129-130.
27. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science. 1977;197:461-463.
28. Sabbath KD, Ball ED, Larcom P, Davis RB, Griffin JD. Heterogeneity of clonogenic cells in acute myeloblastic leukemia. J Clin Invest. 1985;75: 746-753.
29. McCulloch E, Till J. Blast cells in acute myelo-blastic leukemia: a model. Blood Cells. 1981;7: 63-77.
30. Buick RN, Minden MD, McCulloch EA. Self-renewal in culture of proliferative blast progenitor cells in acute myeloblastic leukemia. Blood. 1979;54:95-104.
31. MaximovA. Der lymphozyt als gemeinsame Stammzelle der verschieden Blutelemente in der embryonalen Entwicklung und postfetalen Leben der Sugetiere. Folia Haematologica (Leipzig). 1909;8:125-141.
32. Lichtman MA. The stem cell in the pathogenesis and treatment of myelogenous leukemia: a perspective. Leukemia. 2001;15:1489-1494.
33. Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res. 1961;14:213-222.
34. Becker AJ, McCulloch EA, Till JE. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature. 1963;197:452-454.
35. Siminovitch L, McCulloch EA, Till JE. The distribution of colony-forming cells among spleen colonies. J Cell Comp Physiol. 1963;62:327-336.
36. Till JE, McCulloch EA, Siminovitch L. A stochastic model of stem cell proliferation based on the growth of spleen colony-forming cells. Proc Natl Acad Sci U S A. 1964;51:29-36.
37. Lemischka IR. The haematopoietic stem cell and its clonal progeny: mechanisms regulating the hierarchy of primitive haematopoietic cells. Cancer Surv. 1992;15:3-18.
38. Morrison S, Uchida N, Weissman I. The biology of hematopoietic stem cells. Annu Rev Cell Dev Biol. 1995;11:35-71.
39. McKenzie JL, Gan OI, Doedens M, Wang JC, Dick JE. Individual stem cells with highly variable proliferation and self-renewal properties comprise the human hematopoietic stem cell compartment. Nat Immunol. 2006;7:1225-1233.
40. Sieburg HB, Cho RH, Dykstra B, Uchida N, Eaves CJ, Muller-Sieburg CE. The hematopoietic stem compartment consists of a limited number of discrete stem cell subsets. Blood. 2006;107: 2311-2316.
41. Huang S, Guo YP, May G, Enver T. Bifurcation dynamics in lineage-commitment in bipotent progenitor cells. Dev Biol. 2007;305:695-713.
42. Pluznik DH, Sachs L. The cloning of normal "mast" cells in tissue culture. J Cell Physiol. 1965;66:319-324.
43. Bradley TR, Metcalf D. The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci. 1966;44:287-299.
44. Metcalf D. Hematopoietic cytokines. Blood. 2008;111:485-491.
45. Magli MC, Iscove NN, Odartchenko N. Transient nature of early hematopoietic spleen colonies. Nature. 1982;295:527-529.
46. Boggs DR, Boggs SS, Saxe DF, Gress LA, Canfield DR. Hemopoietic stem cells with high proliferative potential: assay of their concentration in marrow by the frequency and duration of cure of W/Wv mice. J Clin Invest. 1982;70:242-253.
47. Paige CJ, Kincade PW, Moore MAS, Lee G. The fate of fetal and adult B-cell progenitors grafted into immunodeficient CBA/N mice. J Exp Med. 1979;150:548-563.
48. Paige CJ, Kincade PW, Shinefeld LA, Sato VL. Precursors of murine B lymphocytes: physical and functional characterization, and distinctions from myeloid stem cells. J Exp Med. 1981;153: 154-165.
49. Hodgson GS, Bradley TR. Properties of hematopoietic stem cells surviving 5-fluorouracil treatment: evidence for a pre-CFU-S cell? Nature. 1979;281:381-382.
50. Ploemacher RE, Brons RH. Separation of CFU-S from primitive cells responsible for reconstitution of the bone marrow hemopoietic stem cell compartment following irradiation: evidence for a pre-CFU-S cell. Exp Hematol. 1989;17:263-266.
51. Harrison DE. Competitive repopulation: a new assay for long-term stem cell functional capacity. Blood. 1980;55:77-81.
52. Ford C, Hamerton J, Barns W, Loutet J. Cytological identification of radiation chimeras. Nature. 1956;177:452-454.
53. Wu AM, Till JE, Siminovitch L, McCulloch EA. Cytological evidence for a relationship between normal hemopoietic colony-forming cells and cells of the lymphoid system. J Exp Med. 1968;127:455-463.
54. Abramson S, Miller RG, Phillips RA. The identification in adult bone marrow of pluripotent and restricted stem cells of the myeloid and lymphoid systems. J Exp Med. 1977;145:1567-1579.
55. Dick JE, Magli MC, Huszar D, Phillips RA, Bernstein A. Introduction of a selectable gene into primitive stem cells capable of long-term reconsti-tution of the hemopoietic system of W/Wv mice. Cell. 1985;42:71-79.
56. Keller G, Paige C, Gilboa E, Wagner E. Expression of a foreign gene in myeloid and lymphoid cells derived from multipotent hemopoietic precursors. Nature. 1985;318:149-154.
57. Lemischka IR, Raulet DH, Mulligan RC. Developmental potential and dynamic behavior of hema-topoietic stem cells. Cell. 1986;45:917-927.
58. Lorenz E, Uphoff D, Reid TR, Shelton E. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J Natl Cancer Inst. 1951;12:197-201.
59. Thomas ED, Lochte HL Jr, Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med. 1957;257:491-496.
60. Gatti RA, Meuwissen HJ, Allen HD, Hong R, Good RA. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet. 1968;2:1366-1369.
61. Buckner CD, Epstein RB, Rudolph RH, Clift RA, Storb R, Thomas ED. Allogeneic marrow engraft-ment following whole body irradiation in a patient with leukemia. Blood. 1970;35:741-750.
62. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981;292:154-156.
63. Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci U S A. 1981;78:7634-7638.
64. Miller RG, Phillips RA. Separation of cells by velocity sedimentation. J Cell Physiol. 1969;73:191-201.
65. Bonner WA, Hulett HR, Sweet RG, Herzenberg LA. Fluorescence activated cell sorting. Rev Sci Instrum. 1972;43:404-409.
66. Visser JW, Bol SJ, van den Engh G. Characterization and enrichment of murine hemopoietic stem cells by fluorescence activated cell sorting. Exp Hematol. 1981;9:644-655.
67. Baines P, Visser JW. Analysis and separation of murine bone marrow stem cells by H33342 fluorescence-activated cell sorting. Exp Hematol. 1983;11:701-708.
68. Spangrude GJ, Heimfeld S, Weissman IL. Purification and characterization of mouse hematopoi-etic stem cells. Science. 1988;241:58-62.
69. Osawa M, Hanada K, Hamada H, Nakauchi H. Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science. 1996;273:242-245.
70. Kiel MJ, YilmazOH, IwashitaT, YilmazOH, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 2005;121:1109-1121.
71. Benveniste P, Cantin C, Hyam D, Iscove NN. Hematopoietic stem cells engraft in mice with absolute efficiency. Nat Immunol. 2003;4:708-713.
72. Kent DG, Dykstra BJ, Cheyne J, Ma E, Eaves CJ. Steel factor coordinately regulates the molecular signature and biologic function of hematopoietic stem cells. Blood. 2008;112:560-567.
73. Dick JE. Normal and leukemic human stem cells assayed in SCID mice. Semin Immunol. 1996;8: 197-206.
74. Mosier DE, Gulizia RJ, Baird SM, Wilson DB. Transfer of afunctional human immune system to mice with severe combined immunodeficiency. Nature. 1988;335:256-259.
75. McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M, Weissman IL. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science. 1988;241:1632-1639.
76. Fraser CC, Kaneshima H, Hansteen G, Kilpatrick M, Hoffman R, Chen BP. Human allogeneic stem cell maintenance and differentiation in a long-term multilineage SCID-hu graft. Blood. 1995;86: 1680-1693.
77. Baum CM, Weissman IL, Tsukamoto AS, Buckle A-S, Peault B. Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci U S A. 1992;89:2804-2808.
78. Kamel-Reid S, Dick JE. Engraftment of immune-deficient mice with human hematopoietic stem cells. Science. 1988;242:1706-1709.
79. LapidotT, Pflumio F, Doedens M, Murdoch B, Williams DE, Dick JE. Cytokine stimulation of multilineage hematopoiesis from immature human cells engrafted in scidmice. Science. 1992;255:1137-1141.
80. Vormoor J, Lapidot T, Pflumio F, et al. Immature human cord blood progenitors engraft and proliferate to high levels in severe combined immuno-deficient mice. Blood. 1994;83:2489-2497.
81. Shultz L, Schweitzer P, Christianson S, et al. Multiple defects in innate and adaptive immunological function in NOD/LtSz-scid mice. J Immunol. 1995;154:180-191.
82. Larochelle A, Vormoor J, Hanenberg H, et al. Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy. Nat Med. 1996;2:1329-1337.
83. Cashman JD, LapidotT, Wang JC, et al. Kinetic evidence of the regeneration of multilineage hematopoiesis from primitive cells in normal human bone marrow transplanted into immunodeficient mice. Blood. 1997;89:4307-4316.
84. Wang JC, Doedens M, Dick JE. Primitive human hematopoietic cells are enriched in cord blood compared with adult bone marrow or mobilized peripheral blood as measured by the quantitative in vivo SCID-repopulating cell assay. Blood. 1997;89:3919-3924.
85. Conneally E, Cashman J, Petzer A, Eaves C. Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabetic-scid/scid mice. Proc Natl Acad Sci U S A. 1997;94:9836-9841.
86. Ito M, Hiramatsu H, Kobayashi K, et al. NOD/ SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood. 2002;100:3175-3182.
87. Ishikawa F, Yasukawa M, Lyons B, et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chain (null) mice. Blood. 2005;106:1565-1573.
88. Hogan CJ, Shpall EJ, Keller G. Differential long-term and multilineage engraftment potential from subfractions of human CD34+ cord blood cells transplanted into NOD/SCID mice. Proc Natl Acad Sci USA. 2002;99:413-418.
89. KerreTC, De Smet G, De Smedt M, et al. Adapted NOD/SCID model supports development of phenotypically and functionally mature T cells from human umbilical cord blood CD34(+) cells. Blood. 2002;99:1620-1626.
90. McKenzie JL, Gan OI, Doedens M, Dick JE. Human short-term repopulating stem cells are efficiently detected following intrafemoral transplantation into NOD/SCID recipients depleted of CD122+ cells. Blood. 2005;106:1259-1261.
91. Takenaka K, PrasolavaTK, Wang JC, et al. Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nat Immunol. 2007;8:1313-1323.
92. Mazurier F, Doedens M, Gan OI, Dick JE. Rapid myeloerythroid repopulation after intrafemoral transplantation of NOD-SCID mice reveals a new class of human stem cells. Nat Med. 2003;9:959-963.
93. YahataT, Ando K, SatoT, et al. A highly sensitive strategy for SCID-repopulating cell assay by direct injection of primitive human hematopoietic cells into NOD/SCID mice bone marrow. Blood. 2003;101:2905-2913.
94. Wang J, KimuraT, Asada R, et al. SCID-repopulating cell activity of human cord blood-derived CD34-negative cells assured by intra-bone marrow injection. Blood. 2003;101:2924-2931.
95. Wang L, Menendez P, Shojaei F, et al. Generation of hematopoietic repopulating cells from human embryonic stem cells independent of ectopic HOXB4 expression. J Exp Med. 2005;201:1603-1614.
96. Dick JE, Lapidot T Biology of normal and acute myeloid leukemia stem cells. Int J Hematol. 2005;82:389-396.
97. Wang JC, Dorrell C, Ito CY, et al. Normal and leukemic human stem cells assayed in immune-deficient mice. In: Zon LI, ed. Hematopoiesis: A Developmental Approach. New York, NY: Oxford University Press;2001:99-118.
98. Pflumio F, Izac B, Katz A, Shultz LD, Vainchenker W, Coulombel L. Phenotype and function of human hematopoietic cells engrafting immune-deficient CB17-severe combined immunodeficiency mice and nonobese diabetic-severe combined immunodeficiency mice after transplantation of human cord blood mononuclear cells. Blood. 1996;88:3731-3740.
99. Glimm H, Eisterer W, Lee K, et al. Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-beta2 microglobulin-null mice. J Clin Invest. 2001;107:199-206.
100. KerreTC, De Smet G, De Smedt M, et al. Both CD34+38+ and CD34 + 38- cells home specifically to the bone marrow of NOD/LtSZ scid/scid mice but show different kinetics in expansion. J Immunol. 2001;167:3692-3698.
101. GuenecheaG, Gan OI, Dorrell C, Dick JE. Distinct classes of human stem cells that differ in proliferative and self-renewal potential. Nat Immunol. 2001;2:75-82.
102. Mazurier F, Gan O, McKenzie J, Doedens M, Dick J. Lentivector-mediated clonal tracking reveals intrinsic heterogeneity in the human hematopoietic stem cell compartment and culture-induced stem cell impairment. Blood. 2004;103:545-552.
103. Kamel-Reid S, Letarte M, Sirard C, et al. Amodel of human acute lymphoblastic leukemia in immune-deficient SCID mice. Science. 1989;246: 1597-1600.
104. Uckun FM, Sather H, Reaman G, et al. Leukemic cell growth in SCID mice as a predictor of relapse in high-risk B-lineage acute lymphoblastic leukemia. Blood. 1995;85:873-878.
105. Civin C, Strauss L, Brovall C, Fackler M, Schwartz J, Shaper J. Antigenic analysis of he-matopoiesis: III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol. 1984;133: 157-165.
106. Terstappen LW, Safford M, Unterhalt M, et al. Flow cytometric characterization of acute myeloid leukemia: IV. Comparison to the differentiation pathway of normal hematopoietic progenitor cells. Leukemia. 1992;6:993-1000.
107. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645-648.
108. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-737.
109. Ailles LE, Gerhard B, Kawagoe H, Hogge DE. Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood. 1999;94:1761-1772.
110. Terpstra W, Prins A, Visser T, et al. Conditions for engraftment of human acute myeloid leukemia (AML) in SCID mice. Leukemia. 1995;9:1573-1577.
111. Terpstra W, Prins A, Ploemacher RE, et al. Long-term leukemia-initiating capacity of a CD34-sub-population of acute myeloid leukemia. Blood. 1996;87:2187-2194.
112. Pearce DJ, Taussig D, Zibara K, et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood. 2006;107: 1166-1173.
113. van Rhenen A, Feller N, Kelder A, et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res. 2005;11: 6520-6527.
114. Fialkow PJ, Singer JW, Adamson JW, et al. Acute nonlymphocytic leukemia: heterogeneity of stem cell origin. Blood. 1981;57:1068-1073.
115. Fialkow P, Singer J, Raskind W, et al. Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia. N Engl J Med. 1987;317:468-473.
116. Fearon E, Burke P, Schiffer C, Zehnbauer B, Vogelstein B. Differentiation of leukemia cells to polymorphonuclear leukocytes in patients with acute nonlymphoblastic leukemia. N Engl J Med. 1986;315:15-24.
117. Fialkow P, Denman A, Jacobson R, Lowenthal M. Chronic myelogenous leukemia: origin of some lymphocytes from leukemic stem cells. J Clin Invest. 1978;62:815-823.
118. Al-Hajj M, Wicha M, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100: 3983-3988.
119. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396-401.
120. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells - perspectives on current status and future directions: American Association for Cancer Research Workshop on Cancer Stem Cells. Cancer Res. 2006;66:9339-9344.
121. Jordan CT, Lemischka IR. Clonal and systemic analysis of long-term hematopoiesis in the mouse. Genes Dev. 1990;4:220-232.
122. Hope K, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol. 2004;5:738-743.
123. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukemic stem cells. Nature. 2003;423:455-460.
124. Yilmaz OH, Valdez R,Theisen BK, et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature. 2006;441:475-482.
125. Guan Y, Gerhard B, Hogge DE. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood. 2003;101:3142-3149.
126. Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98:2301-2307.
127. Terpstra W, Ploemacher RE, PrinsA, etal. Flu-orouracil selectively spares acute myeloid leukemia cells with long-term growth abilities in immunodeficient mice and in culture. Blood. 1996;88: 1944-1950.
128. So CW, Karsunky H, Passegue E, Cozzio A, Weissman IL, Cleary ML. MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice. Cancer Cell. 2003;3:161-171.
129. Huntly BJ, Shigematsu H, Deguchi K, et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell. 2004;6:587-596.
130. Krivtsov AV, Twomey D, Feng Z, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006;442: 818-822.
131. Cozzio A, Passegue E, Ayton PM, Karsunky H, Cleary ML, Weissman IL. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev. 2003;17:3029-3035.
132. Passegue E, Wagner EF, Weissman IL. JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell. 2004;119:431-443.
133. Chen W, Kumar AR, Hudson WA, et al. Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells. Cancer Cell. 2008;13: 432-440.
134. Wang Y, Armstrong SA. Cancer: inappropriate expression of stem cell programs? Cell Stem Cell. 2008;2:297-299.
135. MiyamotoT, Weissman IL, Akashi K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci USA. 2000;97: 7521-7526.
136. Majeti R, Park C, Weissman I. Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. Cell Stem Cell. 2007;1: 635-645.
137. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351:657-667.
138. Nowell P, Hungerford D. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;132:1497.
139. Rowley JD. A new consistent chromosomal abnormality in myelogenous leukemia identified by quinacrine fluorescence and giemsa staining. Nature. 1973;243:290-293.
140. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704-715.
141. Darley RL, Hoy TG, Baines P, Padua RA, Burnett AK. Mutant N-RAS induces erythroid lineage dysplasia in human CD34+ cells. J Exp Med. 1997;185:1337-1347.
142. Pereira DS, Dorrell C, Ito CY, et al. Retroviral transduction of TLS-ERG initiates a leukemo-genic program in normal human hematopoietic cells. Proc Natl Acad Sci USA. 1998;95:8239-8244.
143. Warner JK, Wang JC,Takenaka K, et al. Direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells. Leukemia. 2005;19:1794-1805.
144. Mulloy JC, Cammenga J, Berguido FJ, et al. Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. Blood. 2003;102: 4369-4376.
145. Chalandon Y, Jiang X, Christ O, et al. BCR-ABL-transduced human cord blood cells produce abnormal populations in immunodeficient mice. Leukemia. 2005;19:442-448.
146. Kennedy JA, BarabéF. Investigating human leu-kemogenesis from cell lines to in vivo models of human leukemia. Leukemia. 2008 Aug 7 [Epub ahead of print].
147. Barabé F, Kennedy JA, Hope KJ, Dick JE. Modeling the initiation and progression of human acute leukemia in mice. Science. 2007;316:600-604.
148. Wei J, Wunderlich M, Fox C, et al. Microenviron-ment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell. 2008;13:483-495.
149. Greaves MF, Wiemels J. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer. 2003;3:639-649.
150. Hong D, Gupta R, Ancliff P, et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science. 2008;319:336-339.
151. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science. 2007;317:337.
152. Williams RT, den Besten W, Sherr CJ. Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia. Genes Dev. 2007;21:2283-2287.
153. Somervaille TC, Cleary ML. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell. 2006;10:257-268.
154. Kennedy JA, Barabé F, Poeppl AG, Wang JC, Dick JE. Comment on "Tumor growth need not be driven by rare cancer stem cells." Science. 2007;318:1722; author reply 1722.
155. Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med. 2007;356:217-226.
156. Guzman ML, Rossi RM, Neelakantan S, et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood. 2007;110:4427-4435.
157. Guzman ML, Li X, Corbett CA, et al. Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). Blood. 2007;110:4436-4444.
158. Hassane DC, Guzman ML, Corbett C, et al. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood. 2008;111:5654-5662.
159. Feuring-Buske M, FrankelA, Gerhard B, Hogge D. Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells. Exp Hematol. 2000;28:1390-1400.
160. Terpstra W, Rozemuller H, Breems DA, et al. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor eliminates acute myeloid leukemia cells with the potential to initiate leukemia in immunodeficient mice, but spares normal hemopoietic stem cells. Blood. 1997;90: 3735-3742.
161. FrankelA, Liu JS, Rizzieri D, Hogge D. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma. 2008;49:543-553.
162. Bonnet D, Warren EH, Greenberg PD, Dick JE, Riddell SR. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci USA. 1999;96:8639-8644.
163. Rosinski KV, Fujii N, Mito JK, et al. DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells. Blood. 2008;111:4817-4826.
164. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006;12: 1167-1174.
165. Tavor S, Petit I, Porozov S, et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res. 2004;64:2817-2824.
166. Papayannopoulou T, Scadden DT. Stem-cell ecology and stem cells in motion. Blood. 2008;111: 3923-3930.
167. Ishikawa F, Yoshida S, Saito Y, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007;25:1315-1321.
168. Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14:1777-1784.
169. Lock R, Jin L, Lee E, et al. CD123 (IL-3 receptor chain) neutralization by a monoclonal antibody selectively eliminates human acute myeloid leu-kemic stem cells. Blood. 2007;110:161.
170. Ito K, Bernardi R, Morotti A, et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature. 2008;453:1072-1078.
171. Wang JC. Evaluating therapeutic efficacy against cancer stem cells: new challenges posed by a new paradigm. Cell Stem Cell. 2007;1:497-501.